Drugs / STR-V003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06344975 | May → Dec 2024 | respiratory syncytial virus infectious disease | Starna Therapeutics | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STR-V003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06344975 ↗ |
| Modality | Messenger RNA (mRNA) | “Respiratory Syncytial Virus (RSV) mRNA Vaccine STR-V003” NCT06344975 ↗ |